Straits Times Index
3,323.20 -6.89 (-0.21%) S&P 500
5,274.08 -31.96 (-0.60%) Dow
38,499.31 -353.55 (-0.91%) Nasdaq
16,955.27 -64.61 (-0.38%) Bitcoin USD
67,748.22 -137.59 (-0.20%) CMC Crypto 200
1,452.84 -31.85 (-2.15%)
MRK Jun 2024 120.000 put
| Previous close | 0.5400 |
| Open | 0.4900 |
| Bid | 0.5200 |
| Ask | 0.6000 |
| Strike | 120.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.4900 - 0.5700 |
| Contract range | N/A |
| Volume | |
| Open interest | 5.98k |
- Reuters SG
Deals of the day-Mergers and acquisitions
** N-Able, a U.S. provider of information technology software with a market value of $2.3 billion, is exploring a sale after attracting acquisition interest, people familiar with the matter said. ** Catalent said its stockholders have voted to approve its buyout deal with Novo Holdings, the parent company of Novo Nordisk.
Business WireFDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
RAHWAY, N.J., May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. The FDA has set a Prescription Drug User Fee
Business WireMerck to Acquire EyeBio
RAHWAY, N.J. & NEW YORK, May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
